New strategies for enzyme replacement therapy for lysosomal storage diseases

Rejuvenation Research

Volumn 13, Issue 2-3, 2010, Pages 229-236

  Grubb, Jeffrey H ^a   Vogler, Carole ^a   Sly, William S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; HEPARAN SULFATE; IMMUNOGLOBULIN FC FRAGMENT; PERIODATE; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BINDING SITE; BIOREMEDIATION; BLOOD BRAIN BARRIER; CELL MEMBRANE; CHIMERA; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME REPLACEMENT; FEMALE; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS; INTERNALIZATION; LYSOSOME STORAGE DISEASE; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME REPLACEMENT THERAPY; GLUCURONIDASE; GLYCOSYLATION; HUMANS; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MICE; PROTEIN SORTING SIGNALS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77952373222     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0920     Document Type: Review

References (33)

1. Wraith JE. Lysosomal disorders. Semin Neonatol 2002;7:75-83.
2. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocer-ebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87:1913-1916.
3. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1470.
4. Kornfeld S. Lysosomal enzyme targeting. Biochem Soc Trans 1990;18:367-374.
5. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J 1987; 1:462-468.
6. Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495-502.
7. Sly WS, Vogler C, Grubb JH, Zhou M, Jiang J, Zhou XY, Tomatsu S, Bi Y, Snella EM. Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice. Proc Natl Acad Sci USA 2001;98:2205-2210.
8. LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C, Sly WS. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mu-copolysaccharidosis type VII mice. Proc Natl Acad Sci USA 2004;101:3083-3088. (Pubitemid 38327738)
9. Orii KO, Grubb JH, Vogler C, Levy B, Tan Y, Markova K, Davidson BL, Mao Q, Orii T, Kondo N, Sly WS. Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther 2005;12:345-352.
10. Grubb JH, Vogler C, Tan Y, Shah GN, MacRae AF, Sly WS. Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopoly-saccharidosis VII mice. Proc Natl Acad Sci USA 2008;105: 8375-8380.
11. Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS. Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine muco-polysaccharidosis VII. Proc Natl Acad Sci USA 2008;105: 2616-2621.
12. Zhao KW, Neufeld EF. Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells. Protein Expr Purif 2000;19: 202-211.
13. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced trans-duction potential in vitro and in vivo. Cancer Res 2001;61: 474-477.
14. Xia H, Mao Q, Davidson BL. The HIV Tat protein trans-duction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001;19:640-644.
15. Vogler C, Levy B, Galvin NJ, Thorpe C, Sands MS, Barker JE, Baty J, Birkenmeier EH, Sly WS. Enzyme replacement in murine mucopolysaccharidosis type VII: Neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 1999;45: 838-844.
16. Cheng Y, Verp MS, Knutel T, Hibbard JU. Mucopoly-saccharidosis type VII as a cause of recurrent non-immune hydrops fetalis. J Perinat Med 2003;31:535-537.
17. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-725.
18. Van de PP. Transfer of antibody via mother's milk. Vaccine 2003;21:3374-3376.
19. Sly WS, Vogler C, Grubb JH, Levy B, Galvin N, Tan Y, NishiokaT,TomatsuS. Enzyme therapyinmannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci USA 2006;103:15172-15177.
20. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, Lee YC, Feizi T, Langen H, Nussenzweig MC. Mannose receptor-mediated regulation of serum glycoprotein ho-meostasis. Science 2002;295:1898-1901.
21. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeo-stasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170:3528-3533.
22. Israel EJ, Patel VK, Taylor SF, Marshak-Rothstein A, Simister NE. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol 1995;154:6246-6251.
23. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101:9763-9768.
24. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med 2006;57:283-296.
25. Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E, Pavloff N, Sly WS. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopo-lysaccharidosis VII. Proc Natl Acad Sci USA 2005;102:14777-14782.
26. Dunder U, Kaartinen V, Valtonen P, Vaananen E, Kosma VM, Heisterkamp N, Groffen J, Mononen I. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J 2000;14:361-367.
27. Roces DP, Lullmann-Rauch R, Peng J, Balducci C, Anders-son C, Tollersrud O, Fogh J, Orlacchio A, Beccari T, Saftig P, von Figura K. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: A preclinical animal study. Hum Mol Genet 2004;13:1979-1988.
28. Matzner U, Herbst E, Hedayati KK, Lullmann-Rauch R, Wessig C, Schroder S, Eistrup C, Moller C, Fogh J, Gie-selmann V. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005;14:1139-1152.
29. Achord DT, Brot FE, Bell CE, Sly WS. Human beta-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978;15:269-278.
30. Hickman S, Shapiro LJ, Neufeld EF. A recognition marker required for uptake of a lysosomal enzyme by cultured fi-broblasts. Biochem Biophys Res Commun 1974;57:55-61.
31. Houba PH, Boven E, Haisma HJ. Improved characteristics of a human beta-glucuronidase-antibody conjugate after de-glycosylation for use in antibody-directed enzyme prodrug therapy. Bioconjug Chem 1996;7:606-611. (Pubitemid 26369626)
32. de Grey AD, Alvarez PJ, Brady RO, Cuervo AM, Jerome WG, McCarty PL, Nixon RA, Rittmann BE, Sparrow JR. Medical bioremediation: Prospects for the application of microbial catabolic diversity to aging and several major age-related diseases. Ageing Res Rev 2005;4:315-338.
33. Rittmann BE, Schloendorn J. Engineering away lysosomal junk: Medical bioremediation. Rejuvenation Res 2007;10:359-365.